All In Biotech

Drug Trial Radar · NCT07676266

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Nov 2027

Study completion Oct 2028

Sponsor

Lead sponsor
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai AbelZeta Ltd.
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Conditions

  • Multiple Sclerosis (MS)
  • Myasthenia Gravis (MG)
  • Neuromyelitis Optica Spectrum Disorder
  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
  • Immune-Mediated Necrotizing Myopathy

Interventions

  • CD20/BCMA-directed CAR-T cells Autologous 2nd generationBiological

    CD20/BCMA-directed CAR-T cells, single infusion intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events [Safety and Tolerability]Time frame: Throughout the first 3 months follow up period completion
  2. The subsequent recommended dose of C-CAR168 in patients with autoimmune diseases refractory to standard therapyTime frame: Throughout the first 24 months follow up period completion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Qingdao University

    Qingdao, Qindao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.